Capricor Therapeutics (STU:4LN2) Net Issuance of Debt : €0.00 Mil (TTM As of Dec. 2024)

View and export this data going back to 2017. Start your Free Trial

What is Capricor Therapeutics Net Issuance of Debt?

Net issuance of debt is the cash a company received or spent through debt related activities such as debt issuance or debt repayment. If a company pays down its debt during the period, this number will be negative. If a company issued more debt, it receives cash and this number is positive. Capricor Therapeutics's net issuance of debt for the three months ended in Dec. 2024 was €0.00 Mil. Its net issuance of debt for the trailing twelve months (TTM) ended in Dec. 2024 was €0.00 Mil.

Capricor Therapeutics Net Issuance of Debt Historical Data

The historical data trend for Capricor Therapeutics's Net Issuance of Debt can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Capricor Therapeutics Net Issuance of Debt Chart

Capricor Therapeutics Annual Data

Trend

Dec15

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

Dec24

Net Issuance of Debt

Get a 7-Day Free Trial

0.26

Capricor Therapeutics Quarterly Data
	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23	Mar24	Jun24	Sep24	Dec24
Net Issuance of Debt	Get a 7-Day Free Trial															-	-	-	-	-

Capricor Therapeutics Net Issuance of Debt Calculation

This is the cash a company received or spent through debt related activities such as debt issuance or debt repayment. If a company pays down its debt during the period, this number will be negative. If a company issued more debt, it receives cash and this number is positive.

Net Issuance of Debt for the trailing twelve months (TTM) ended in Dec. 2024 adds up the quarterly data reported by the company within the most recent 12 months, which was €0.00 Mil.

Capricor Therapeutics Net Issuance of Debt Related Terms

Thank you for viewing the detailed overview of Capricor Therapeutics's Net Issuance of Debt provided by GuruFocus.com. Please click on the following links to see related term pages.

Capricor Therapeutics Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Capricor Therapeutics Inc (STU:4LN2) » Definitions » Net Issuance of Debt

Comparable Companies

Traded in Other Exchanges

CAPR:USA 4LN2:Germany

Address

10865 Road to the Cure, Suite 150, San Diego, CA, USA, 92121

Website

https://www.capricor.com

Capricor Therapeutics Inc is a clinical-stage biotechnology company focused on the development of transformative cell and exosome-based therapeutics for treating Duchenne muscular dystrophy (DMD), a rare form of muscular dystrophy which results in muscle degeneration and premature death, and other diseases with high unmet medical needs. The company's product pipeline includes CAP-1002, deramiocel an allogeneic cardiac-derived cell therapy. Deramiocel is currently advancing through Phase 3 clinical development for the treatment of Duchenne muscular dystrophy. Through its proprietary StealthXTM platform, the group uses its exosome technology to conduct preclinical research focused on vaccinology, delivering oligonucleotides, proteins, and small molecules to treat.

Capricor Therapeutics Headlines

No Headlines